US Drug Enforcement Agency increases fentanyl production cap to meet COVID-19 treatment needs

The US Drug Enforcement Agency (DEA) has temporarily lifted a cap on fentanyl production. The Aggregate Production Quota (APQ) for fentanyl production was reduced by 31% in December 2019 to reduce supply in response to the opioid crisis in the US. However, fentanyl is commonly used when placing patients on ventilators and so there has been increased demand for fentanyl from medical practitioners since the beginning of the COVID-19 pandemic.